Ticagrelor alone versus ticagrelor plus aspirin from month 1 to month 12 after percutaneous coronary intervention in patients with acute coronary syndromes (ULTIMATE-DAPT): a randomised, placebo-controlled, double-blind clinical trial (vol 403, pg 1866, 2024)

被引：0
|
作者：
Ge, Z.
Kan, J.
Gao, X.
机构：
来源：
LANCET | 2024年 / 403卷 / 10439期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：1854 / 1854
页数：1
相关论文
共 23 条
  • [11] Expression of Concern: Effect of Adding Ticagrelor to Standard Aspirin on Saphenous Vein Graft Patency in Patients Undergoing Coronary Bypass Grafting (POPular CABG): A Randomized Double-Blind, Placebo-Controlled Trial (Expression of Concern of Vol 142, Pg 1799, 2020)
    不详
    CIRCULATION, 2021, 143 (09) : E755 - E755
  • [12] Among patients with acute coronary syndrome who underwent percutaneous coronary intervention with contemporary stents and had no ischemic or hemorrhagic events during 1 month on dual antiplatelet therapy, does treatment with ticagrelor alone between the 1st and 12th month reduce the risk of clinically relevant bleeding while remaining effective in preventing vascular complications compared to ticagrelor combined with aspirin?
    Lanthier, Luc
    Couture, Etienne L.
    Plourde, Marc-Emile
    Cauchon, Michel
    REVUE DE MEDECINE INTERNE, 2024, 45 (08): : 519 - 520
  • [13] Sabatolimab plus hypomethylating agents in previously untreated patients with higher-risk myelodysplastic syndromes (STIMULUSMDS1): a randomised, double-blind, placebo-controlled, phase 2 trial (Vol 11, pg E38, 2024)
    Zeidan, A. M.
    Ando, K.
    Rauzy, O.
    LANCET HAEMATOLOGY, 2024, 11 (03): : e181 - e181
  • [14] Effect of Adding Ticagrelor to Standard Aspirin on Saphenous Vein Graft Patency in Patients Undergoing Coronary Artery Bypass Grafting (POPular CABG) A Randomized, Double-Blind, Placebo-Controlled Trial (Publication with Expression of Concern. See vol. 143, 2021)
    Willemsen, Laura M.
    Janssen, Paul W. A.
    Peper, Joyce
    Soliman-Hamad, Mohamed A.
    van Straten, Albert H. M.
    Klein, Patrick
    Hackeng, Chris M.
    Sonker, Uday
    Bekker, Margreet W. A.
    von Birgelen, Clemens
    Brouwer, Marc A.
    van der Harst, Pim
    Vlot, Eline A.
    Deneer, Vera H. M.
    Yin, Dean R. P. P. Chan Pin
    Gimbel, Marieke E.
    Beukema, Kasper F.
    Daeter, Edgar J.
    Kelder, Johannes C.
    Tijssen, Jan G. P.
    Rensing, Benno J. W. M.
    van Es, Hendrik W.
    Swaans, Martin J.
    ten berg, Jurrien M.
    CIRCULATION, 2020, 142 (19) : 1799 - 1807
  • [15] Low-dose interleukin-2 in patients with stable ischaemic heart disease and acute coronary syndromes (LILACS): protocol and study rationale for a randomised, double-blind, placebo-controlled, phase I/II clinical trial
    Zhao, Tian Xiao
    Kostapanos, Michalis
    Griffiths, Charmaine
    Arbon, Emma L.
    Hubsch, Annette
    Kaloyirou, Fotini
    Helmy, Joanna
    Hoole, Stephen P.
    Rudd, James H. F.
    Wood, Graham
    Burling, Keith
    Bond, Simon
    Cheriyan, Joseph
    Mallat, Ziad
    BMJ OPEN, 2018, 8 (09):
  • [16] Extended antiplatelet therapy with clopidogrel alone versus clopidogrel plus aspirin after completion of 9-to 12-month dual antiplatelet therapy for acute coronary syndrome patients with both high bleeding and ischemic risk. Rationale and design of the OPT-BIRISK double-blinded, placebo-controlled randomized trial
    Li, Yi
    Jing, Quanmin
    Wang, Bing
    Wang, Xiaozeng
    Li, Jing
    Qiao, Shubing
    Chen, Shaoliang
    Angiolillo, Dominick J.
    Han, Yaling
    AMERICAN HEART JOURNAL, 2020, 228 : 1 - 7
  • [17] Otamixaban for the treatment of patients with non-ST-elevation acute coronary syndromes (SEPIA-ACS1 TIMI 42): a randomised, double-blind, active-controlled, phase 2 trial (vol 374, pg 787, 2009)
    Sabatine, M. S.
    Antman, E. M.
    Widimsky, P.
    LANCET, 2009, 374 (9700): : 1502 - 1502
  • [18] Simeprevir with pegylated interferon alfa 2a plus ribavirin in treatment-naive patients with chronic hepatitis C virus genotype 1 infection (QUEST-1): a phase 3, randomised, double-blind, placebo-controlled trial (vol 384, pg 403, 2014)
    Jacobson, I. M.
    Dore, G. J.
    Foster, G. R.
    LANCET, 2016, 387 (10030): : 1816 - 1816
  • [19] Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 76-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 1) - (vol 371, pg 1665, 2008)
    Leonardi, C. L.
    Kimball, A. B.
    Papp, K. A.
    LANCET, 2008, 371 (9627): : 1838 - 1838
  • [20] Letter of comment on "Intracoronary nitroprusside for the prevention of the no-reflow phenomenon after primary percutaneous coronary intervention in acute myocardial infarction.: A randomized, double-blind, placebo-controlled clinical trial" (Am Heart J 2006; 152:887.e9-14)
    Vydt, Tom
    Agostoni, Pierfrancesco
    AMERICAN HEART JOURNAL, 2007, 153 (05)
123